Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.2 CHF | 0.00% | -5.72% | +5.96% |
Feb. 14 | BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 19 | BB Biotech Names Successor to Outgoing Chair | MT |
Business Summary
- listed companies (99.9%): primarily Ionis Pharmaceuticals (rare diseases), Gilead Sciences (infectious viral diseases and flu), Celgene Corporation (cancer and inflammation of the immune system), Esperion Therapeutics (cardio-metabolic diseases), Vertex Pharmaceuticals (infectious diseases and diseases of the immune system) and Incyte (cancers, hematologic disorders and inflammatory diseases);
- other (0.1%).
Number of employees: 10
Sales per Business
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biotechnology
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -57.97% |
Sales per region
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Switzerland
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -57.97% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel Koller
CIO | Chief Investment Officer | 54 | 03-12-31 |
- | - | ||
- | - | ||
Felicia Flanigan
PRN | Corporate Officer/Principal | - | 03-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Clive Meanwell
BRD | Director/Board Member | 67 | 03-12-31 |
Director/Board Member | 63 | 19-12-31 | |
Chairman | 63 | 19-03-20 | |
Director/Board Member | 67 | 22-03-16 | |
Laura Hamill
BRD | Director/Board Member | 60 | 22-03-16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 55,400,000 | 53,870,953 ( 97.24 %) | 554,000 ( 1.000 %) | 97.24 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
8,590,000 | 5.89% | 388,353,900 $ | |
SAGE THERAPEUTICS, INC. 5.83% | 3,505,000 | 5.83% | 75,287,400 $ |
BB BIOTECH AG 1.00% | 554,000 | 1.00% | 28,815,174 $ |
WAVE LIFE SCIENCES LTD. 3.78% | 4,494,458 | 3.78% | 21,618,343 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Biotech Focus NV
| |
Biotech Invest NV
| |
Biotech Target NV
Biotech Target NV MiscellaneousMiscellaneous Part of Bellevue Group AG, Biotech Target NV is a holding Dutch company. The private company is located in Netherlands. |
Miscellaneous
|
Biotech Growth NV
Biotech Growth NV Financial ConglomeratesFinance Part of Bellevue Group AG, Biotech Growth NV is a Dutch company that provides blank check company services. The private company is located in Netherlands. |
Financial Conglomerates
|
Sector
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+5.96% | 2.74B | |
+9.16% | 45.97B | |
+54.31% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |
- Stock
- Equities
- Stock BB Biotech AG - Swiss Exchange
- Company BB Biotech AG